A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial
2015
EuroIntervention
Aims: To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and randomised use, outcome data ≥3 years are relatively scarce.
doi:10.4244/eijy14m08_11
pmid:25136888
fatcat:kvadzk5ukvgmfl66ajjhi4mgvq